Molecular therapies and vaccines face the challenges of emerging infectious diseases

Affiliations

¹ The Wistar Institute, Philadelphia, PA 19104, USA. Electronic address: apatel@wistar.org.
² The Wistar Institute, Philadelphia, PA 19104, USA.
³ Indiana University School of Medicine, Indianapolis, IN 46202-3082, USA.
⁴ The University of Edinburgh, Edinburgh EH16 4TJ, UK.
⁵ University of Ghent, Merelbeke, 9820 Merelbeke, Belgium.

Editorial

Ami Patel et al. Mol Ther. 2022.

. 2022 May 4;30(5):1789-1790.

doi: 10.1016/j.ymthe.2022.04.003. Epub 2022 Apr 16.

¹ The Wistar Institute, Philadelphia, PA 19104, USA. Electronic address: apatel@wistar.org.
² The Wistar Institute, Philadelphia, PA 19104, USA.
³ Indiana University School of Medicine, Indianapolis, IN 46202-3082, USA.
⁴ The University of Edinburgh, Edinburgh EH16 4TJ, UK.
⁵ University of Ghent, Merelbeke, 9820 Merelbeke, Belgium.

No abstract available

References

1. Cai C., Liu Y., Zeng S., Shen H., Han Y. The efficacy of COVID-19 vaccines against the B.1.617.2 (delta) variant. Mol. Ther. 2021;29:2890–2892. doi: 10.1016/j.ymthe.2021.09.024. - DOI - PMC - PubMed
1. Cai C., Peng Y., Shen E., Huang Q., Chen Y., Liu P., Guo C., Feng Z., Gao L., Zhang X., et al. A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. Mol. Ther. 2021;29:2794–2805. doi: 10.1016/j.ymthe.2021.08.001. - DOI - PMC - PubMed
1. Zhang S., Wang L., Cheng G. The battle between host and SARS-CoV-2: innate immunity and viral evasion strategies. Mol. Ther. 2022 doi: 10.1016/j.ymthe.2022.02.014. - DOI - PMC - PubMed
1. Coughlan L., Kremer E.J., Shayakhmetov D.M. Adenovirus-based vaccines-a platform for pandemic preparedness against emerging viral pathogens. Mol. Ther. 2022 doi: 10.1016/j.ymthe.2022.01.034. - DOI - PMC - PubMed
1. Szabo G.T., Mahiny A.J., Vlatkovic I. COVID-19 mRNA vaccines: platforms and current developments. Mol. Ther. 2022 doi: 10.1016/j.ymthe.2022.02.016. - DOI - PMC - PubMed